CDKN1A and neoplasm: We conducted qPCR experiments for p53 targets Bax, Puma, CDKN1A, and MDM2 to further verify that blocking p53 signaling with knock-down of TP53 abrogated the ability of MDM4 inhibition to activate the p53 tumor suppressor signaling pathway.